Multispecific binding molecules comprising connecting peptides

Details Multispecific binding molecules comprising connecting peptides Multispecific binding molecules comprising connecting peptides

2007-07-05

2011-12-27

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S136100, C424S143100, C424S192100, C530S387300, C530S388220

Reexamination Certificate

active

08084026

ABSTRACT:
The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

REFERENCES:
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5082783 (1992-01-01), Ernst et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208020 (1993-05-01), Chari et al.
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5641870 (1997-06-01), Rinderknecht et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5795964 (1998-08-01), Browning et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 5837821 (1998-11-01), Wu
patent: 5859205 (1999-01-01), Adair et al.
patent: 5877291 (1999-03-01), Mezes et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6063905 (2000-05-01), Capra et al.
patent: 6066719 (2000-05-01), Zapata
patent: 6071515 (2000-06-01), Mezes et al.
patent: 6207815 (2001-03-01), Mezes et al.
patent: 6214984 (2001-04-01), Zapata
patent: 6218149 (2001-04-01), Morrison et al.
patent: 6284536 (2001-09-01), Morrison et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6329507 (2001-12-01), Mezes et al.
patent: 6348581 (2002-02-01), Anderson et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 6552170 (2003-04-01), Thompson et al.
patent: 6576746 (2003-06-01), McBride et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 6737056 (2004-05-01), Presta
patent: 6759518 (2004-07-01), Kontermann et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 2002/0002271 (2002-01-01), Rinderknecht et al.
patent: 2002/0009446 (2002-01-01), Magilavy
patent: 2002/0028486 (2002-03-01), Morrison et al.
patent: 2002/0062010 (2002-05-01), Arathoon et al.
patent: 2002/0155109 (2002-10-01), Lynch
patent: 2002/0197254 (2002-12-01), Browning et al.
patent: 2003/0060444 (2003-03-01), Finney et al.
patent: 2003/0078385 (2003-04-01), Arathoon et al.
patent: 2003/0207346 (2003-11-01), Arathoon et al.
patent: 2004/0033511 (2004-02-01), Pfizenmaier et al.
patent: 2004/0058394 (2004-03-01), Garber et al.
patent: 2004/0101905 (2004-05-01), Brekke et al.
patent: 2004/0198635 (2004-10-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0097625 (2005-05-01), Meade et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0104971 (2006-05-01), Garber et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0222644 (2006-10-01), Garber et al.
patent: 2006/0280722 (2006-12-01), Browning et al.
patent: 2007/0154476 (2007-07-01), Browning et al.
patent: 0327378 (1989-08-01), None
patent: 0509553 (1992-10-01), None
patent: 0519596 (1992-12-01), None
patent: WO-89/07142 (1989-08-01), None
patent: WO-91/09967 (1991-07-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/09817 (1994-05-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-94/20625 (1994-09-01), None
patent: WO-95/09917 (1995-04-01), None
patent: WO-95/22389 (1995-08-01), None
patent: WO-96/22788 (1996-08-01), None
patent: WO-97/03687 (1997-02-01), None
patent: WO-97/11370 (1997-03-01), None
patent: WO-99/15549 (1999-04-01), None
patent: WO-99/38525 (1999-08-01), None
patent: WO-99/58679 (1999-11-01), None
patent: WO-02/30986 (2002-04-01), None
patent: WO-02/060955 (2002-08-01), None
patent: WO-02/066516 (2002-08-01), None
patent: WO-02/085946 (2002-10-01), None
patent: WO-02/088170 (2002-11-01), None
patent: WO-02/096948 (2002-12-01), None
patent: WO-2004/026427 (2004-04-01), None
patent: WO-2004/029207 (2004-04-01), None
patent: WO-2004/042017 (2004-05-01), None
patent: WO-2004/074434 (2004-09-01), None
patent: WO-2005/000899 (2005-01-01), None
patent: WO-2005/092927 (2005-10-01), None
Hudson et al, J. Immunological Method 231: 177-189, 1999.
Aalberse, R.C., et al. “IgG4 breaking the rules.”Immunology. 2002; 105:9-19.
Adams, Gregory P., et al., “Highly Specific in Vivo Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv1,”Cancer Research, vol. 53:4026-4034 (1993).
Adkins, Heather B. et al, “Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo,”The Journal of Clinical Investigation, vol. 112(4):575-587 (2003).
Alderson, Mark R. et al., “Regulation of apoptosis and T cell activation by Fas-specific mAb,”International Immunology, vol. 6(11):1799-1806 (1994).
Alimzhanov, Marat B. et al., “Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice,”Proc. Natl. Acad. Sci. USA, vol. 94:9302-9307 (1997).
Alt, Margitta, et al., “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γl Fc or CH3 region,”FEBS Letters, vol. 454:90-94 (1999).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry, vol. 267(4):2542-2547 (1992).
Angal, S., et al. “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody.”Molecular Immunology. 1993; 30(1):105-8.
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Baens, Mathus et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid,”Genomics, vol. 16:214-218 (1993).
Banks, Theresa A. et al., “Lymphotoxin-α-Deficient Mice,”The Journal of Immunology, vol. 155:1685-1693 (1995).
Benhar, Itai, et al., “PseudomonasExotoxin A Mutants,”The Journal of Biological Chemistry, vol. 269(18):13398-13404 (1994).
Bera, Tapan K., et al., “A Bivalent Disulfide-stabilized Fv with Improved Antigen Binding to erbB2,”J. Mol. Biol., vol. 281:475-483 (1998).
Bernstein, David I. et al., “Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development,”Antiviral Research, vol. 20:45-55 (1993).
Bloom,

Affiliated with

Also associated with

Rating

Multispecific binding molecules comprising connecting peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multispecific binding molecules comprising connecting peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multispecific binding molecules comprising connecting peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4270733